FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01418222 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: 5-FU
DRUG: FOLFOX regimen
DRUG: Placebo
DRUG: bevacizumab [Avastin]
DRUG: leucovorin
DRUG: onartuzumab [MetMAb]

Sponsor

Genentech, Inc.

Collaborators

[object Object]